Κυριακή 7 Ιανουαρίου 2018

Rare Tumors in Kids May Respond to Tazemetostat [News in Brief]

In a phase I trial of the EZH2 inhibitor tazemetostat, children with INI1-deficient tumors—including relapsed or refractory malignant rhabdoid tumors, atypical teratoid rhabdoid tumors, epithelioid sarcomas, and poorly differentiated chordomas—responded well to treatment, with some experiencing durable responses.



http://ift.tt/2CRE060

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου